On May 10, the medical website of the pharmaceutical industry, from the perspective of treatment, pharmaceutical companies and other perspectives, analyzed the pharmaceutical industry leaders in 2016 (12 months to December 31, 2016). 

 

The treatment field is ranked at home and abroad 

 

According to statistics, the global pharmaceutical market in 2016 was $10,098.0 million for the first time, breaking the $1 trillion for the first time. Subdivided into the treatment market, the number of anti-tumor and immunoregulatory medication was ranked 1st (see chart 1), with 16.46.4 billion dollars, 16.3% of the market share; The second is the digestive and metabolic drugs, accounting for 14.8%; The third, fourth, and five were the neurological, systemic and cardiovascular system drugs, 13.4%, 12.8% and 8.9% respectively. 

 

 

 

PDB data according to the Chinese pharmaceutical industry information center, 2016 samples of domestic hospital of 20 categories divided therapeutic area total purchasing amount is 1661 8, one hundred million yuan, up 9.1% from a year earlier. This data suggests that the overall market growth rate of hospital medicine (in 2015, the year-on-year growth rate was 6.6 percent). 

 

The market performance of 20 treatment categories in domestic sample hospitals is shown in table 1, which is different from the sorting of the global pharmaceutical market treatment category. The domestic sample hospital was still at the top of the list, but its drug use fell to 15.1 percent from 26.1 percent in 2005, down 11 percent. The problem of living environment and air quality is becoming more and more serious, and the amount of drug medication for the respiratory system is higher than that of the previous year, which is up to 12.5%. With the higher the incidence of cancer and the aging of the population proportion increase antitumor medicine, endocrine and metabolic regulation sum of year-on-year growth rate is higher, at about 10%. 

 

 

 

Pfizer is a global leader, with astrazeneca leading the way 

 

In 2016, Pfizer topped the global pharmaceutical industry with sales of $47.54 billion. Pfizer medicines involving the main therapeutic areas of the immunology and inflammation, central nervous system, urogenital system, cardiovascular drugs, metabolic diseases and cancer drugs, etc. Product categories include biological products, small molecules, vaccines and consumer products. Currently, Pfizer's blockbuster products are Pregabalin, which has more than $6 billion in sales in 2016. 

 

The 10 leading pharmaceutical companies in the global pharmaceutical industry in 2016 saw figure 2. Top 10 sales totaled $37918 million, accounting for 37.6 percent of the global pharmaceutical market. 

 

 

 

According to the PDB data, in 2016, domestic leading leading company sample hospitals purchasing amount of astrazeneca, the amount is 3.49 billion yuan, accounting for 2.1% of the sample hospitals purchasing amount, the main sales varieties of budesonide, goserelin, propofol, and the treatment of metoprolol,; The second name is qilu pharmaceutical co., LTD., is 3.22 billion yuan, accounting for 2.1%, mainly sales variety of single sialic acid four hexose ganglioside, pemetrexed, recombinant human granulocyte stimulating factor, interleukin - 11, the Dan SiQiong; Third is jiangsu hengrui medicine co., LTD., is 3.19 billion yuan, accounting for 1.9%, mainly sells varieties with the right mi, he sai dorsey, atracurium, iodine, alcohol, stand for kang; The fourth is novartis, which accounts for 3.04 billion yuan, or 1.8 percent. Fifth is sanofi company, is 2.71 billion yuan, accounting for 1.6%, the main sales varieties of oxaliplatin into, insulin, blood albumin, dorsey his race, in accordance with heparin. In 2016, the leading companies in the domestic sample hospitals are table 2. 

 

 

 

epilogue 

 

1. The sales amount of the leading 10 therapeutic areas at home and abroad the sum subtotal broadly similar percentage accounted for the overall market, global and domestic accounted for 89.4% (9026.6 billion dollar /.0 versus $9026), 87.2% (1449 activity have yuan/RMB 1661). 

 

Domestic pharmaceutical companies are not among the Top 10 companies in the world by sales. Domestic leading pharmaceutical companies compared with the world's leading pharmaceutical companies, small scale, low sales and profits, r&d, product is given priority to with generic drugs, new drug market was monopolized by the international big company products.